What is Regado Biosciences Earnings Yield (Joel Greenblatt) %?
Regado Biosciences's Enterprise Value for the quarter that ended in Jun. 2016 was $0.00 Mil.
Regado Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2016 was $-60.16 Mil. Regado Biosciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2016 was -28.57%.
The historical rank and industry rank for Regado Biosciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
RGDO'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2581.3 Med: 0 Max: 10697.7
Current: -7.85
During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Regado Biosciences was 10697.70%. The lowest was -2581.30%. And the median was 0.00%.
RGDO's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -15.17
vs RGDO: -7.85
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Regado Biosciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2016 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Regado Biosciences Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Regado Biosciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regado Biosciences's Earnings Yield (Joel Greenblatt) %
For the Biotechnology subindustry, Regado Biosciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regado Biosciences's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regado Biosciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Regado Biosciences's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Regado Biosciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2015 is calculated as
Regado Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.16 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Regado Biosciences Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Regado Biosciences's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Regado Biosciences (Regado Biosciences) Business Description
Regado Biosciences Inc was incorporated in Delaware under the name Quartet Biosciences, Inc. in December 2001 and changed its name to Regado Biosciences, Inc. in March 2003. It is a biopharmaceutical company. The Company is engaged in the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company's product candidates consists of a two-component system: an aptamer and its specific active control agent. The aptamer is administered first and achieves its therapeutic effect within minutes. When the therapeutic effect of the aptamer is no longer needed, the control agent is administered to rapidly and precisely reduce or eliminate it. The level of reduction is determined by the amount of control agent given compared to the aptamer dose. The Company's product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. The Company is developing REG1 as an anticoagulant for use in patients with cardiovascular conditions undergoing percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGDO has been successfully added to your 